@article{jfnr20142810,
author={{Pe?a, Francisca and Mizgier, Maria Luisa and Morales, Pamela and Rios, Israel and Carrasco-Pozo, Catalina and Diaz, Erik and Brunser, Oscar and Gotteland, Martin},
title={Effect of the Synbiotic (<i>B. animalis </i>spp. <i>lactis </i>Bb12 + Oligofructose) in Obese Subjects. A Randomized, Double-Blind, Controlled Clinical Trial},
journal={Journal of Food and Nutrition Research},
volume={2},
number={8},
pages={491--498},
year={2014},
url={http://pubs.sciepub.com/jfnr/2/8/10},
issn={2333-1240},
abstract={Rats fed high fat diets have alterations of their intestinal microbiota, gut barrier function, circulating lipopolysaccharide (LPS) levels and biomarkers of oxidative stress, inflammation, and glucose/insulin metabolism, resulting in a higher risk of type-2 diabetes. These deleterious effects are prevented by antibiotics or prebiotics. The aim of this study was to determine whether the administration of a synbiotic improves metabolic alterations and low grade inflammation in obese subjects. A randomized, double-blind, controlled clinical trial (www.ClinicalTrials.gov, Access Number NCT01235026) was carried out in 40 obese patients. Subjects were distributed in two groups to receive 8g oligofructose + 1 g of lyophilized <i>Bifidobacterium lactis </i>Bb12 (1010 CFU/g) or 9g maltodextrin as placebo, twice a day for six weeks. Body composition, blood lipids, antioxidant capacity of plasma, biomarkers of inflammation (usCRP, IL-6) and LPS exposure (LPS-Binding Protein, LBP, and sCD14), areas under curves of glycemia and insulinemia and fecal microbiota (qPCR) were quantified at baseline and after treatment. 38 subjects (34.8 ¡À 9.2y; BMI: 36.7 ¡À 5.3 kg.m-2) completed the study. A positive correlation was observed at baseline between usCRP, IL-6, LBP, sCD14 and the percentage of body fat; correlations also existed between usCRP, IL-6 and LBP values while sCD14 only correlated with IL-6. Compared with placebo, the administration of synbiotic increased the fecal levels of <i>Bifidobacterium </i>spp. but did not affect body composition, lipid profile, antioxidant status and areas under curves of glycemia and insulinemia, nor the plasma concentrations of usCRP, IL-6 and LBP. Plasma concentrations of sCD14 were significantly lower after treatment in the symbiotic group compared with the placebo 3 group (5.98 ¦Ìg/ml [5.01-6.96] vs. 7.26 [6.34-8.09] ¦Ìg/ml (Means [CI95%), respectively; p=0.043). The synbiotic increased fecal bifidobacteria in obese subjects without improvement the biochemical, inflammatory and metabolic markers; more studies are required to elucidate the role of the symbiotic on plasma sCD14.},
doi={10.12691/jfnr-2-8-10}
publisher={Science and Education Publishing}
}